Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Венозные тромбоэмболии: что нового в лечении и профилактике
Венозные тромбоэмболии: что нового в лечении и профилактике
Симпозиум компании «Пфайзер»: «Венозные тромбоэмболии: что нового в лечении и профилактике». Consilium Medicum. 2020; 22 (12): 97–101. DOI: 10.26442/20751753.2020.12.200471
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
________________________________________________
Полный текст
Список литературы
1. Khorana AA, Francis CW, Culakova E et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (3): 632–4.
2. Garfield.
3. Carrier M, Prandoni P. Controversies in the management of cancer-associated thrombosis. Expert Rev Hematol 2017; 10 (1): 15–22.
4. Рекомендации ESC/ERS, 2014.
[Rekomendatsii ESC/ERS, 2014 (in Russian).]
5. Schulman S, Goldhaber SZ, Kearon C et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015; 114: 150–7.
6. Prins MH, Lensing AW, Brighton TA et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1 (1): e37–46.
7. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 2015; 13 (12): 2187–91.
8. Raskob GE, van Es N, Verhamme P et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615–24.
9. Young AM, Marshall A, Thirlwall J et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SEL ECT-D). J Clin Oncol 2018; 36: 2017–23.
10. McBane RD, Wysokinski WE, Le-Rademacher J et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (2): 411–21. DOI: 10.1111/jth.14662
11. Agnelli G, Becattini C, Meyer G et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17): 1599–607.
12. Рекомендации ЕКО по ТЭЛА, 2019.
Rekomendatsii EKO po TELA, 2019 (in Russian).]
13. Kearon C., Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease. CHEST Guideline and Expert Panel Report. CHEST 2016; 149 (2): 315–52.
14. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799–808.
15. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–510.
16. Büller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–97.
17. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–52.
18. Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. Circulation 2014; 129: 764–72.
19. Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699–708.
20. Flaker GC, Theriot P, Binder LG et al. Management of Periprocedural Anticoagulation: A Survey of Contemporary Practice. J Am Coll Cardiol 2016; 68 (2): 217–26.
21. Уддин Л.Н., Егоров А.В., Соколова А.А. и др. Особенности тромбоэмболических и геморрагических осложнений при плановых хирургических вмешательствах у больных с фибрилляцией предсердий. Рацион. фармакотерапия в кардиологии. 2019; 15 (3): 315–21. DOI: 10.20996/1819-6446-2019-15-3-315-321
[Uddin L.N., Egorov A.V., Sokolova A.A. et al. Features of Thromboembolic and Hemorrhagic Complications in Planned Surgical Interventions in Patients with Atrial Fibrillation. Rational Pharmacother Cardiol. 2019; 15 (3): 315–21. DOI: 10.20996/1819-6446-2019-15-3-315-321 (in Russian).]
22. Steinberg BA, Peterson ED, Kim S et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Investigators and Patients. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings fr om the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015; 131 (5): 488–94.
23. Rechenmacher SJ, Fang JC. Bridging Anticoagulation: Primum Non Nocere. J Am Coll Cardiol 2015; 66: 1392–403.
24. Douketis JD, Spyropoulos AC, Duncan J et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med 2019; 179 (11): 1469–78.
2. Garfield.
3. Carrier M, Prandoni P. Controversies in the management of cancer-associated thrombosis. Expert Rev Hematol 2017; 10 (1): 15–22.
4. Rekomendatsii ESC/ERS, 2014 (in Russian).
5. Schulman S, Goldhaber SZ, Kearon C et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015; 114: 150–7.
6. Prins MH, Lensing AW, Brighton TA et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1 (1): e37–46.
7. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 2015; 13 (12): 2187–91.
8. Raskob GE, van Es N, Verhamme P et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615–24.
9. Young AM, Marshall A, Thirlwall J et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SEL ECT-D). J Clin Oncol 2018; 36: 2017–23.
10. McBane RD, Wysokinski WE, Le-Rademacher J et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (2): 411–21. DOI: 10.1111/jth.14662
11. Agnelli G, Becattini C, Meyer G et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17): 1599–607.
12. Rekomendatsii EKO po TELA, 2019 (in Russian).
13. Kearon C., Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease. CHEST Guideline and Expert Panel Report. CHEST 2016; 149 (2): 315–52.
14. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799–808.
15. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–510.
16. Büller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–97.
17. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–52.
18. Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. Circulation 2014; 129: 764–72.
19. Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699–708.
20. Flaker GC, Theriot P, Binder LG et al. Management of Periprocedural Anticoagulation: A Survey of Contemporary Practice. J Am Coll Cardiol 2016; 68 (2): 217–26.
21. Uddin L.N., Egorov A.V., Sokolova A.A. et al. Features of Thromboembolic and Hemorrhagic Complications in Planned Surgical Interventions in Patients with Atrial Fibrillation. Rational Pharmacother Cardiol. 2019; 15 (3): 315–21. DOI: 10.20996/1819-6446-2019-15-3-315-321 (in Russian).
22. Steinberg BA, Peterson ED, Kim S et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Investigators and Patients. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings fr om the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015; 131 (5): 488–94.
23. Rechenmacher SJ, Fang JC. Bridging Anticoagulation: Primum Non Nocere. J Am Coll Cardiol 2015; 66: 1392–403.
24. Douketis JD, Spyropoulos AC, Duncan J et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med 2019; 179 (11): 1469–78.
2. Garfield.
3. Carrier M, Prandoni P. Controversies in the management of cancer-associated thrombosis. Expert Rev Hematol 2017; 10 (1): 15–22.
4. Рекомендации ESC/ERS, 2014.
[Rekomendatsii ESC/ERS, 2014 (in Russian).]
5. Schulman S, Goldhaber SZ, Kearon C et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015; 114: 150–7.
6. Prins MH, Lensing AW, Brighton TA et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1 (1): e37–46.
7. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 2015; 13 (12): 2187–91.
8. Raskob GE, van Es N, Verhamme P et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615–24.
9. Young AM, Marshall A, Thirlwall J et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SEL ECT-D). J Clin Oncol 2018; 36: 2017–23.
10. McBane RD, Wysokinski WE, Le-Rademacher J et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (2): 411–21. DOI: 10.1111/jth.14662
11. Agnelli G, Becattini C, Meyer G et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17): 1599–607.
12. Рекомендации ЕКО по ТЭЛА, 2019.
Rekomendatsii EKO po TELA, 2019 (in Russian).]
13. Kearon C., Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease. CHEST Guideline and Expert Panel Report. CHEST 2016; 149 (2): 315–52.
14. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799–808.
15. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–510.
16. Büller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–97.
17. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–52.
18. Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. Circulation 2014; 129: 764–72.
19. Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699–708.
20. Flaker GC, Theriot P, Binder LG et al. Management of Periprocedural Anticoagulation: A Survey of Contemporary Practice. J Am Coll Cardiol 2016; 68 (2): 217–26.
21. Уддин Л.Н., Егоров А.В., Соколова А.А. и др. Особенности тромбоэмболических и геморрагических осложнений при плановых хирургических вмешательствах у больных с фибрилляцией предсердий. Рацион. фармакотерапия в кардиологии. 2019; 15 (3): 315–21. DOI: 10.20996/1819-6446-2019-15-3-315-321
[Uddin L.N., Egorov A.V., Sokolova A.A. et al. Features of Thromboembolic and Hemorrhagic Complications in Planned Surgical Interventions in Patients with Atrial Fibrillation. Rational Pharmacother Cardiol. 2019; 15 (3): 315–21. DOI: 10.20996/1819-6446-2019-15-3-315-321 (in Russian).]
22. Steinberg BA, Peterson ED, Kim S et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Investigators and Patients. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings fr om the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015; 131 (5): 488–94.
23. Rechenmacher SJ, Fang JC. Bridging Anticoagulation: Primum Non Nocere. J Am Coll Cardiol 2015; 66: 1392–403.
24. Douketis JD, Spyropoulos AC, Duncan J et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med 2019; 179 (11): 1469–78.
________________________________________________
2. Garfield.
3. Carrier M, Prandoni P. Controversies in the management of cancer-associated thrombosis. Expert Rev Hematol 2017; 10 (1): 15–22.
4. Rekomendatsii ESC/ERS, 2014 (in Russian).
5. Schulman S, Goldhaber SZ, Kearon C et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015; 114: 150–7.
6. Prins MH, Lensing AW, Brighton TA et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1 (1): e37–46.
7. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 2015; 13 (12): 2187–91.
8. Raskob GE, van Es N, Verhamme P et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615–24.
9. Young AM, Marshall A, Thirlwall J et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SEL ECT-D). J Clin Oncol 2018; 36: 2017–23.
10. McBane RD, Wysokinski WE, Le-Rademacher J et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (2): 411–21. DOI: 10.1111/jth.14662
11. Agnelli G, Becattini C, Meyer G et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17): 1599–607.
12. Rekomendatsii EKO po TELA, 2019 (in Russian).
13. Kearon C., Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease. CHEST Guideline and Expert Panel Report. CHEST 2016; 149 (2): 315–52.
14. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799–808.
15. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–510.
16. Büller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–97.
17. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–52.
18. Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. Circulation 2014; 129: 764–72.
19. Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699–708.
20. Flaker GC, Theriot P, Binder LG et al. Management of Periprocedural Anticoagulation: A Survey of Contemporary Practice. J Am Coll Cardiol 2016; 68 (2): 217–26.
21. Uddin L.N., Egorov A.V., Sokolova A.A. et al. Features of Thromboembolic and Hemorrhagic Complications in Planned Surgical Interventions in Patients with Atrial Fibrillation. Rational Pharmacother Cardiol. 2019; 15 (3): 315–21. DOI: 10.20996/1819-6446-2019-15-3-315-321 (in Russian).
22. Steinberg BA, Peterson ED, Kim S et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Investigators and Patients. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings fr om the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015; 131 (5): 488–94.
23. Rechenmacher SJ, Fang JC. Bridging Anticoagulation: Primum Non Nocere. J Am Coll Cardiol 2015; 66: 1392–403.
24. Douketis JD, Spyropoulos AC, Duncan J et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med 2019; 179 (11): 1469–78.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.